Top

Published in:

01-01-2012 | Original Paper

Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo

Authors: Sankarganesh Arunachalam, Sun Young Kim, Sun Hwa Lee, Young Hee Lee, Min Sun Kim, Bong Sik Yun, Ho Keun Yi, Pyoung Han Hwang

Published in: Journal of Natural Medicines | Issue 1/2012

Abstract

Adriamycin (ADR) is a potent anticancer drug. Its clinical applications are limited due to its cardiotoxicity. Oxidative stress is responsible for cardiomyopathy induced by ADR. Previous studies have demonstrated that davallialactone (DAVA), extracted from mushroom Inonotus xeranticus, has potential antiplatelet aggregation activity and free radical scavenging properties. In this study, we investigated whether DAVA has protective effects against ADR-induced free radical accumulation and apoptosis in cardiac muscle cells and compared the effects of DAVA with N-acetylcysteine, a potent antioxidant. We evaluated the effect of DAVA on ADR-induced cytotoxicity by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and crystal violet staining, the reactive oxygen species (ROS) production by flow cytometry, and the expression of stress-related proteins like Cu/Zn superoxide dismutase (SOD), Mn-SOD, and the involvement of mitogen-activated protein kinase pathway by Western blot analysis. Apoptosis was assessed by nuclear condensation and the expression levels of pro-apoptotic proteins, such as caspase-3 and polyadenosine diphosphate-ribose polymerase (PARP). The cardio-protective effects of DAVA were also evaluated in an in vivo study in an animal model of ADR-induced acute cardiomyopathy. Our results showed that DAVA significantly increased the viability of doxorubicin-injured H9c2 cells and inhibited ADR-induced ROS production, apoptosis, and the expression of Cu/Zn SOD and Mn-SOD. DAVA also inhibited the expression of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), which was activated by ADR. In the in vivo animal model, treatment involving DAVA significantly reduced cardiomyocyte lesions. These results suggest that DAVA is a potentially protective agent for ADR-induced cardiotoxicity in cardiomyocytes and can be a potential candidate to protect against cardiotoxicity in ADR-treated cancer patients.

Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, Wojnowski L (2007) Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med 42:466–473PubMedCrossRef

Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C, Barsotti A (2006) Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69:736–745PubMedCrossRef

Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorov EA, Kotamraju S (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234–235:119–124PubMedCrossRef

Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B (2000) Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 275:33585–33592PubMedCrossRef

Sawyer DB, Fukazawa R, Arstall MA, Kelly RA (1999) Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84:257–265PubMed

Haunstetter A, Izumo S (1998) Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 82:1111–1129PubMed

Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305:139–153PubMedCrossRef

Lindequist U, Niedermeyer TH, Jülich WD (2005) The pharmacological potential of mushrooms. Evid Based Complement Alternat Med 2:285–299PubMedCrossRef

Ooi VE, Liu F (2000) Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem 7:715–729PubMed

10.

Imazeki R, Hongo T (1989) Colored illustrations of mushrooms of Japan. Hoikusha, Osaka

11.

Kim SD, Lee IK, Lee WM, Cho JY, Park HJ, Oh JW, Park SC, Kim SK, Kwak YS, Yun BS, Rhee MH (2008) The mechanism of anti-platelet activity of davallialactone: involvement of intracellular calcium ions, extracellular signal-regulated kinase 2 and p38 mitogen-activated protein kinase. Eur J Pharmacol 584:361–367PubMedCrossRef

12.

Lee YG, Lee WM, Kim JY, Lee JY, Lee IK, Yun BS, Rhee MH, Cho JY (2008) Src kinase-targeted anti-inflammatory activity of davallialactone from Inonotus xeranticus in lipopolysaccharide-activated RAW264.7 cells. Br J Pharmacol 154:852–863PubMedCrossRef

13.

Lee IK, Yun BS (2006) Hispidin analogs from the mushroom Inonotus xeranticus and their free radical scavenging activity. Bioorg Med Chem Lett 16:2376–2379PubMedCrossRef

14.

Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T, Schlattner U (2005) Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol 289:H37–H47PubMedCrossRef

15.

DeAtley SM, Aksenov MY, Aksenova MV, Jordan B, Carney JM, Butterfield DA (1999) Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology 134:51–62PubMedCrossRef

16.

Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK (2001) Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 3:135–145PubMedCrossRef

17.

Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E (2000) Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 102:572–578PubMed

18.

Sugden PH, Clerk A (1998) Regulation of mitogen-activated protein kinase cascades in the heart. Adv Enzyme Regul 38:87–98PubMedCrossRef

19.

Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326–1331PubMedCrossRef

20.

Wang X, Martindale JL, Liu Y, Holbrook NJ (1998) The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 333:291–300PubMed

21.

Mizukami Y, Okamura T, Miura T, Kimura M, Mogami K, Todoroki-Ikeda N, Kobayashi S, Matsuzaki M (2001) Phosphorylation of proteins and apoptosis induced by c-Jun N-terminal kinase1 activation in rat cardiomyocytes by H₂O₂ stimulation. Biochim Biophys Acta 1540:213–220PubMedCrossRef

22.

Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW Jr, Billingham ME (1983) Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 99:745–749PubMed

23.

Lores Arnaiz S, Llesuy S (1993) Oxidative stress in mouse heart by antitumoral drugs: a comparative study of doxorubicin and mitoxantrone. Toxicology 77:31–38PubMedCrossRef

24.

Van Vleet JF, Ferrans VJ, Weirich WE (1980) Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 99:13–42PubMed

25.

Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R, Chua BH (2002) Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 283:H254–H263PubMed

26.

Yamanaka S, Tatsumi T, Shiraishi J, Mano A, Keira N, Matoba S, Asayama J, Fushiki S, Fliss H, Nakagawa M (2003) Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol 41:870–878PubMedCrossRef

27.

Andrieu-Abadie N (2004) Cardiotoxicity of anthracyclines: mechanisms and pharmacologic targets for prevention. Therapie 59(1):121–126PubMedCrossRef

28.

Yen HC, Oberley TD, Gairola CG, Szweda LI, St Clair DK (1999) Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys 362:59–66PubMedCrossRef

29.

Daosukho C, Chen Y, Noel T, Sompol P, Nithipongvanitch R, Velez JM, Oberley TD, St Clair DK (2007) Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. Free Radic Biol Med 42:1818–1825PubMedCrossRef

30.

Kumar D, Lou H, Singal PK (2002) Oxidative stress and apoptosis in heart dysfunction. Herz 27:662–668PubMedCrossRef

Title: Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo
Authors: Sankarganesh Arunachalam
Sun Young Kim
Sun Hwa Lee
Young Hee Lee
Min Sun Kim
Bong Sik Yun
Ho Keun Yi
Pyoung Han Hwang
Publication date: 01-01-2012
Publisher: Springer Japan
Published in: Journal of Natural Medicines / Issue 1/2012
Print ISSN: 1340-3443
Electronic ISSN: 1861-0293
DOI: https://doi.org/10.1007/s11418-011-0567-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Genetic diversity of Centella asiatica in China analyzed by inter-simple sequence repeat (ISSR) markers: combination analysis with chemical diversity

New advanced glycation end-products inhibitors from Dichrostachys cinerea Wight & Arn.

Vascular relaxation induced by aqueous extract of Lespedeza cuneata via the NO-cGMP pathway

Herbal formula HMC05 prevents human aortic smooth muscle cell migration and proliferation by inhibiting the ERK1/2 MAPK signaling cascade

Phenolic lipid ingredients from cashew nuts

Factors affecting podophyllotoxin yield in the ex situ grown Podophyllum hexandrum, an endangered alpine native of the western Himalayas